INTRODUCTION
The gag gene products of human immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS, are synthesized as a polyprotein precursor, p55, which is cleaved during particle maturation. The resulting products are pl7, the matrix protein which is anchored into the viral or infected cell membrane by N-terminal myristic acid modification, p24 forming the nucleocapsid and p 15, which is further processed into p9 and p6
and shows association with the viral RNA.'~4 Antibodies directed against gag gene products appear early in HI V infection and are reported to decline with progression of the disease due to increasing antigenemia of p24, a phenomenon which may be used as prognostic marker for alteration of the patient's clinical status.510 Since amino acid sequences encoded by the gag genes are highly conserved in various HIV-1 isolates' ' and also show a high degree of homology with HIV-2, antibodies directed especially to p24 may serve as a preferential diagnostic marker as well for early diagnosis as in follow-up studies of the infected patients during antiviral treatment. Tests using viral or recombinant p24 antigen on Western blots are, however, hampered by a significant degree of antibody-cross-reactions present in sera of not-infected human individuals. An enzyme-linked immunosorbent assay (ELISA) based on synthetic peptide antigens, where only conserved predominantly and specifically reacting compounds may be used should be able to avoid those effects representing an optimal test system. Furthermore, due to their particle-forming capacity,1213 recombinant gag products may serve as potential vaccine candidate, which allow the inclusion of additional epitopes from other HIV-encoded proteins. A precondition for those developments is the exact immunological characterization of the individual domains present in gag-derived amino acid sequences. For this reason we synthesized 41 peptides spanning the whole gag polyprotein precursor, each about 24 residues in length overlapping with each other by 12 For the ELISA competition assay, first the optimal concentration of the recombinant p24 protein was estimated by titration. The recombinant protein (Mikrogen GmbH, Munich, FRG) comprises the whole sequence of p24, including 12 aa of pl7 at the N-terminal part and 74 aa of pi5 at the C-terminus. The proteins were coated at 20 ng/well and incubated with serum dilutions from 1:100 to 1:1600. The sera were preincubated with pooled peptides (peptides 100 p,g/assay), which spanned the whole sequence of recombinant protein p24.
RESULTS

Selected peptides
Forty-one peptides spanning the gag polyprotein precursor molecule (isolate HTLV-III/BH10;1) were synthesized. For length, peptides of 24 residues were selected, since these are able to form secondary structural motives and thus should allow not only the detection of antibodies directed to sequential epitopes but also of those directed to antigenic domains defined by structural properties to form a-helical, ß-pleated sheet or ß-turn protein regions. Possibly both ways-activation of endogenous retrovirus sequences in postnatal life leading to a primed immune system with the production of specific antibodies, which may crossreact with similar domains on one side or activation during embryonic development as a result of clonal deletion of the respective T cells-may contribute to the highly diverse and complicated immune reaction found in humans to gag products during HIV infection.
